Autolus Therapeutics (Autolus Therapeutics) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Autolus Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-26.31 Mil. Autolus Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Autolus Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Autolus Therapeutics's current FCF Yield % is -14.76%.

The historical rank and industry rank for Autolus Therapeutics's FCF Margin % or its related term are showing as below:

AUTL' s FCF Margin % Range Over the Past 10 Years
Min: -54726.86 Med: -4131.77 Max: -965.68
Current: -9221.02

During the past 8 years, the highest FCF Margin % of Autolus Therapeutics was -965.68%. The lowest was -54726.86%. And the median was -4131.77%.

AUTL's FCF Margin % is ranked worse than
91.35% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs AUTL: -9221.02

Autolus Therapeutics FCF Margin % Historical Data

The historical data trend for Autolus Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics FCF Margin % Chart

Autolus Therapeutics Annual Data

Trend

Sep16

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4,131.77

-54,726.86

-8,408.63

-1,988.20

-9,221.02

Autolus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-397.36	-3,563.54	-	-10,267.49	-

Competitive Comparison of Autolus Therapeutics's FCF Margin %

For the Biotechnology subindustry, Autolus Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's FCF Margin % falls into.

Autolus Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Autolus Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-156.573	/	1.698
	=	-9,221.02 %

Autolus Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-26.31	/	0
	=	%

Autolus Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Autolus Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Autolus Therapeutics (Autolus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

6A3A:Germany

Address

191 Wood Lane, The MediaWorks, London, GBR, W12 7FP

Website

https://www.autolus.com

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.